Synaffix out-licenses ADC technology to Elevation Oncology

USA-based Elevation Oncology (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza (SIX: LONN).

As a result, Netherlands-based Synaffix has granted Elevation Oncology global access to its clinical stage, site-specific antibody-drug conjugates (ADC) technology platform, including GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as the toxSYN linker-payload, SYNstatin E, which enables the transformation of Elevation Oncology’s antibody into a differentiated ADC with best-in-class potential.

Deal worth up to $368 million